Search

Heron Therapeutics Inc

Lezárt

SzektorEgészségügy

0.42

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

0.41

Maximum

0.43

Fő mutatók

By Trading Economics

Bevétel

-5.2M

-8.1M

Értékesítés

-5.9M

35M

Egy részvényre jutó nyereség

-0.04

Profit margin

-23.367

Munkavállalók

128

EBITDA

-6.8M

-7.6M

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

+365.12% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. aug. 7.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-149M

81M

Előző nyitás

0.42

Előző zárás

0.42

Hangulat hírek alapján

By Acuity

50%

50%

164 / 342 Rangsor szerint Healthcare

Heron Therapeutics Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. júl. 6. 23:41 UTC

Correlated Moves
Social Media
News

Micron Technology shares are lower in after-market trading, reflecting broader market pressures and concerns over a potential memory oversupply by 2028.

2026. júl. 6. 23:31 UTC

Correlated Moves
News
Social Media

Microsoft Corp announced layoffs of about 4,800 employees, primarily in its Xbox division. Shares are lower in after-market trading following the news.

2026. júl. 6. 23:26 UTC

Correlated Moves
News

Analog Devices Inc. is advancing in after-market trading, driven by a rebound in the semiconductor sector and bullish updates from UBS and Goldman Sachs.

2026. júl. 6. 23:02 UTC

Social Media
News

Vertex Pharmaceuticals shares declined in after-market hours following its $10 billion acquisition of Crinetics Pharmaceuticals at $85 per share, expected to close in 2026.

2026. júl. 6. 20:51 UTC

News
Correlated Moves

Invesco CurrencyShares Euro Trust is gaining in after-market trading, influenced by comments from Federal Reserve Governor Christopher Waller on monetary policy complexities.

2026. júl. 6. 20:07 UTC

News

Verisign shares are higher amid reported $1.1 billion in free cash flow, though concerns linger over AI advancements and upcoming contract renewals.

2026. júl. 6. 20:07 UTC

News
Social Media

Netflix Inc faces engagement issues, prompting bearish investor sentiment. The stock is trading lower amid concerns ahead of its upcoming earnings report.

2026. júl. 6. 20:07 UTC

Social Media
News
Macro Event

PayPal Holdings Inc. shares are lower as recent ISM Services data showed a slowdown in growth, with the PMI declining from the previous month.

2026. júl. 6. 20:07 UTC

Correlated Moves
News

Ethereum is advancing, supported by Tom Lee's BitMine purchasing $74 million in the asset, raising their total holdings to 5,742,237 ETH.

2026. júl. 6. 20:07 UTC

Correlated Moves
News

Bitcoin trades higher, recovering from earlier lows, amid stable cryptocurrency market conditions and concerns over inflation and interest rates. Current price is $61,750.

2026. júl. 6. 20:07 UTC

News
Correlated Moves

Bitcoin's value has risen since Sunday, reaching around $61,750. This increase occurs amid broader cryptocurrency market weakness and concerns over inflation and interest rates.

2026. júl. 6. 20:07 UTC

Social Media
News

Adobe Inc. shares are lower amid scrutiny of first-quarter results and competitive pressures from Canva and Figma, with support noted at $215.

2026. júl. 6. 20:07 UTC

News
Social Media

Apple Inc. shares are higher following an extended partnership with Broadcom for custom chips through 2031 and the reintroduction of card payments in India.

2026. júl. 6. 20:06 UTC

Event
News

Cisco Systems Inc shares are higher today as the company went ex-dividend, distributing $0.42 per share, amid positive analyst upgrades.

2026. júl. 6. 20:06 UTC

News

Ulta Beauty Inc. shares are lower amid declines in the Other Specialty Retail sub-sector and broader market weakness, trading near the bottom of its one-month range.

2026. júl. 6. 20:06 UTC

Social Media
News

Scotiabank upgraded Check Point Software to Sector Outperform, setting a price target of $185, following its 2025 ESG Report release. Shares are higher since Thursday's close.

2026. júl. 6. 20:06 UTC

News

Cintas Corp shares are lower today, continuing a broader market decline since Thursday. The stock peaked early but has trended downward since.

2026. júl. 6. 20:06 UTC

News

Cadence Design Systems reported first-quarter revenue of $1.474 billion, an 18.7% year-over-year increase, and a record backlog of $8 billion. Shares are trading higher.

2026. júl. 6. 20:06 UTC

News

Amgen shares are lower as Cantor Fitzgerald maintains a Neutral rating with a $350 price target, reflecting cautious investor sentiment amid recent volatility.

2026. júl. 6. 20:04 UTC

News
Social Media

Tesla shares are higher today, fueled by strong second-quarter delivery figures and the positive reception of its robotaxi service in Miami.

2026. júl. 6. 20:02 UTC

News

Align Technology shares are higher today following a rating upgrade to "strong-buy" from Wall Street Zen, despite a downgrade from Weiss Ratings.

2026. júl. 6. 20:02 UTC

News

Mondelez International shares are lower amid weakness in the Packaged Foods & Meats sector. The stock remains near the lower end of its one-month trading range.

2026. júl. 6. 20:02 UTC

News
Social Media
Correlated Moves

Qualcomm's stock rises as Nvidia's CEO endorses its AI tech and Bernstein raises its price target. A partnership with Meta also boosts investor interest.

2026. júl. 6. 20:02 UTC

News
Social Media

Gilead Sciences is trading lower amid a Biotechnology sector decline, despite HSBC's upgrade to Buy and a raised price target of $155.

2026. júl. 6. 20:02 UTC

Macro Event
News

J B Hunt shares decline after Morgan Stanley downgraded the stock to Underweight, raising the price target to $200 from $190 amid sector concerns.

2026. júl. 6. 19:57 UTC

News
Social Media

Berkshire Hathaway has tripled its stake in Alphabet, boosting investor sentiment. Alphabet's inclusion in the Dow Jones further underscores its growth potential.

2026. júl. 6. 19:56 UTC

News

Natural gas is trading higher today, maintaining an upward trajectory above its 20-day moving average. ProShares Ultra Bloomberg Natural Gas has gained since Thursday's close.

2026. júl. 6. 19:53 UTC

News

Charter Communications Inc is declining amid low demand for services and stagnant returns on capital. Analysts rate the stock as "Reduce," reflecting a cautious outlook.

2026. júl. 6. 19:52 UTC

Social Media
News

Evercore ISI raised its price target on Illumina to $200, maintaining an Outperform rating. Shares are trading higher amid positive sentiment and social media discussions.

2026. júl. 6. 19:51 UTC

Social Media
News

Bank of America upgraded T-Mobile US Inc to Buy, maintaining a $220 price target, citing overstated competition concerns and the company's urban market dominance.

Társak összehasonlítása

Árváltozás

Heron Therapeutics Inc Előrejelzés

Célár

By TipRanks

365.12% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 2 USD  365.12%

Magas 2 USD

Alacsony 2 USD

2 Wall Street elemző 12 hónapos célárain alapulva a(z)Heron Therapeutics Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

2 ratings

1

Vétel

1

Tartás

0

Eladás

Hangulat

By Acuity

164 / 342 Rangsor szerint Egészségügy

Hangulat hírek alapján

Neutral

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat